Utah is currently home to 1240 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study to Evaluate Safety and Immunogenicity of a Prime-Boost Regimen of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects
NCT06221813
Recruiting
The goal of this clinical trial is to test the safety and immunogenicity of PHV02 live, attenuated recombinant vesicular stomatitis virus vaccine expressing the Nipah Virus glycoprotein in healthy adult subjects. The main questions it aims to answer are: which doses of PHV02 are safe to administer to and well-tolerated by healthy adult subjects as a 2 dose regimen given 1 month apart? what is the immunologic response (Nipah-specific IgG ELISA antibody and neutralizing antibodies) to each dose l... Read More
Gender:
All
Ages:
Between 18 years and 59 years
Trial Updated:
04/17/2024
Locations: Cenexel JBR (JBR Clinical Research), Salt Lake City, Utah
Conditions: Nipah Virus Infection
Register for Updates
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308
Recruiting
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast cancer that is advanced or has spread to another part of the body. Study participation could last up to 5 years.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Utah Cancer Specialists, Salt Lake City, Utah
Conditions: Breast Neoplasms, Neoplasm Metastasis
Register for Updates
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
NCT03425279
Recruiting
The objective of this study is to assess the safety and efficacy of mecbotamab vedotin (BA3011) in solid tumors.
Gender:
All
Ages:
12 years and above
Trial Updated:
04/17/2024
Locations: University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
Register for Updates
One MORE for Chronic Pain in Latinos
NCT06316713
Recruiting
This study will be a single-site, two-arm randomized controlled trial conducted among Spanish-speaking chronic pain patients. Chronic pain patients will be randomized by a computer-generated randomization schedule with simple random allocation (1:1) to either One MORE or a wait-list control condition (WLC). One MORE will be delivered individually either in-person or via a HIPAA compliant virtual meeting platform.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Chronic Pain
Register for Updates
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma
NCT05879367
Recruiting
The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM
Register for Updates
A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases
NCT05755035
Recruiting
The main aim of this study is to evaluate the PK, safety, tolerability and immunogenicity of subcutaneous (SC) administration of TAK-881 in adult and pediatric participants with PIDD and compare them to HYQVIA in participants 16 years old and older. The participants will be treated with TAK-881/HYQVIA or HYQVIA/TAK-881 with the same dose and dosing interval of immunoglobulin for up to 51 weeks (for participants greater than or equal to [>=]16 years) and only with TAK-881 for up to 27 weeks (for... Read More
Gender:
All
Ages:
2 years and above
Trial Updated:
04/16/2024
Locations: Tanner Clinic, Murray, Utah
Conditions: Primary Immunodeficiency Diseases (PID)
Register for Updates
Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study
NCT05677880
Recruiting
This is an observational study to better understand the risk factors and progression of CADASIL, a leading cause of vascular cognitive impairment and dementia (VCID). 500 participants will be enrolled and can expect to be on study for up to 5 years.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: CADASIL
Register for Updates
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
NCT05001737
Recruiting
The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis and adult onset Still's disease) or with sHLH/MAS in systemic lupus erythematous, resenting an inadequate response to high dose glucocorticoid treatment.
Gender:
All
Ages:
Between 6 months and 80 years
Trial Updated:
04/16/2024
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS
Register for Updates
Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma
NCT04919122
Recruiting
ODYSSEY RCC is a prospective, observational Phase IV study is to understand the cancer management and health-related quality of life in patients with mRCC in routine real-world clinical practice in the United States, including both community and academic treatment settings.
Gender:
All
Ages:
19 years and above
Trial Updated:
04/16/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Metastatic Renal Cell Carcinoma
Register for Updates
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
NCT04816604
Recruiting
This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/16/2024
Locations: University of Utah Health, Salt Lake City, Utah
Conditions: Pulmonary Arterial Hypertension
Register for Updates
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
NCT04323046
Recruiting
This phase I trial studies the side effects of nivolumab before and after surgery in treating children and young adults with high grade glioma that has come back (recurrent) or is increasing in scope or severity (progressive). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
All
Ages:
Between 6 months and 25 years
Trial Updated:
04/16/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Grade III Glioma, Grade III Glioma
Register for Updates
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
NCT04266249
Recruiting
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or b... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: Farmington Health Center, Farmington, Utah
Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
Register for Updates